ATE309247T1 - Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate - Google Patents

Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate

Info

Publication number
ATE309247T1
ATE309247T1 AT03717210T AT03717210T ATE309247T1 AT E309247 T1 ATE309247 T1 AT E309247T1 AT 03717210 T AT03717210 T AT 03717210T AT 03717210 T AT03717210 T AT 03717210T AT E309247 T1 ATE309247 T1 AT E309247T1
Authority
AT
Austria
Prior art keywords
tetrahydropyrimido
pyridinyl
pyrimidinyl
pyrimidine
derivatives
Prior art date
Application number
AT03717210T
Other languages
English (en)
Inventor
Alistair Lochead
Alain Nedelec
Mourad Saady
Philippe Yaiche
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02290486A external-priority patent/EP1348708A1/de
Priority claimed from EP02290485A external-priority patent/EP1340758A1/de
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE309247T1 publication Critical patent/ATE309247T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
AT03717210T 2002-02-28 2003-02-26 Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate ATE309247T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02290486A EP1348708A1 (de) 2002-02-28 2002-02-28 Heteroarylsubstituierte 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
EP02290485A EP1340758A1 (de) 2002-02-28 2002-02-28 Heteroarylsubstituierte 2-Pyridinyl-6,7,8,9-tetrahydro[1,2-a]pyridin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
PCT/EP2003/002651 WO2003072579A1 (en) 2002-02-28 2003-02-26 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
ATE309247T1 true ATE309247T1 (de) 2005-11-15

Family

ID=27767034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03717210T ATE309247T1 (de) 2002-02-28 2003-02-26 Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate

Country Status (22)

Country Link
US (2) US7232827B2 (de)
EP (1) EP1480983B1 (de)
JP (1) JP4458851B2 (de)
KR (1) KR101030629B1 (de)
CN (1) CN1315832C (de)
AR (1) AR038619A1 (de)
AT (1) ATE309247T1 (de)
AU (1) AU2003221500B9 (de)
BR (1) BR0308109A (de)
CA (1) CA2474823C (de)
DE (1) DE60302221T2 (de)
DK (1) DK1480983T3 (de)
EA (1) EA007737B1 (de)
ES (1) ES2250883T3 (de)
IL (1) IL163287A (de)
MX (1) MXPA04008364A (de)
NO (1) NO329805B1 (de)
NZ (1) NZ534466A (de)
PL (1) PL372465A1 (de)
SI (1) SI1480983T1 (de)
TW (1) TWI303637B (de)
WO (1) WO2003072579A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408186A (pt) * 2003-03-07 2006-04-04 Sanofi Aventis derivados de 2-(diaza-biciclo-alquil)-pirimidona substituìdos
EP1454910A1 (de) 2003-03-07 2004-09-08 Sanofi-Synthelabo Substitutierte Pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidonederivate
EP1557417B1 (de) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituierte 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one Derivate
WO2005083105A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2448940B1 (de) * 2009-07-02 2014-05-21 Sanofi 6,7,8,9-Tetrahydro-pyrimido{1,2-a} pyrimidin-4-onderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
AR077446A1 (es) 2009-07-02 2011-08-31 Sanofi Aventis Derivados de 2,3-dihidro-1h-imidazo(1,2-a) pirimidin-5-ona. su preparacion y su utilizacion farmaceutica
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
CN102715186A (zh) * 2012-06-15 2012-10-10 王学权 一种增效除草组合物
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
CA2944308A1 (en) * 2014-04-01 2015-10-08 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2968804T3 (es) * 2017-05-24 2024-05-14 Abbisko Therapeutics Co Ltd Derivado de azaarilo, método de preparación del mismo y uso farmacéutico del mismo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038955A1 (es) * 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
JP2004507546A (ja) * 2000-09-01 2004-03-11 サノフィ−サンテラボ ２−ピリジニル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オンおよび７−ピリジニル−２，３−ジヒドロイミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体

Also Published As

Publication number Publication date
NZ534466A (en) 2006-04-28
AU2003221500B9 (en) 2008-11-20
AU2003221500C1 (en) 2008-10-02
EA007737B1 (ru) 2006-12-29
BR0308109A (pt) 2005-01-04
US20050222172A1 (en) 2005-10-06
AU2003221500A1 (en) 2003-09-09
NO329805B1 (no) 2010-12-20
AR038619A1 (es) 2005-01-19
TW200402421A (en) 2004-02-16
DE60302221D1 (de) 2005-12-15
EA200400936A1 (ru) 2005-02-24
US7232827B2 (en) 2007-06-19
DE60302221T2 (de) 2006-08-03
JP2005519086A (ja) 2005-06-30
SI1480983T1 (sl) 2006-04-30
WO2003072579A1 (en) 2003-09-04
AU2003221500B2 (en) 2008-02-14
TWI303637B (en) 2008-12-01
MXPA04008364A (es) 2005-07-26
NO20043565L (no) 2004-11-25
US7465737B2 (en) 2008-12-16
JP4458851B2 (ja) 2010-04-28
PL372465A1 (en) 2005-07-25
EP1480983A1 (de) 2004-12-01
EP1480983B1 (de) 2005-11-09
US20070225300A1 (en) 2007-09-27
ES2250883T3 (es) 2006-04-16
IL163287A (en) 2009-12-24
CN1649871A (zh) 2005-08-03
CA2474823C (en) 2011-02-22
KR101030629B1 (ko) 2011-04-20
CN1315832C (zh) 2007-05-16
DK1480983T3 (da) 2006-03-27
CA2474823A1 (en) 2003-09-04
KR20040087333A (ko) 2004-10-13

Similar Documents

Publication Publication Date Title
ATE309247T1 (de) Heteroaryl substituierte 2-pyridinyl und 2- pyrimidinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-onderivate
CY2017011I2 (el) 2-(ΠΥΡΙΔΙΝ-2-ΥΛΑΜΙΝΟ)-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΥΝ-7-ΟΝΕΣ
ATE284214T1 (de) Imidazo(1,2-a)-pyridinderivate als mglur5 antagonisten
ATE466012T1 (de) Pyrazolo 3,4-b pyridinverbindungen und ihre verwendung als phosphodiesterase inhibitoren
DE60311101D1 (de) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido und 2,3-dihydro-2h-pyrrolo (2,1-b)-chinazolinon-derivate
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
ATE387445T1 (de) Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
DE50301941D1 (de) Derivate-1h-pyrazolo (3, 4-b) -5-(4-pyridinyl)-4-pyrimidinamins und ihre verwendung als guanylatcyclase-stimulatoren
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
ATE445615T1 (de) Pyrido(2,1-a)isochinolinderivative als dpp-iv- hemmer
DE60222006D1 (de) Heterozyklische verbindungen und ihre verwendungen
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
DE60319951D1 (de) Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
NO20042980L (no) 3,4-dihydro-1H-isokinolin-2-yl-derivater
NO20031412L (no) Substituerte 3,4-dihydro-pyrido[1,2-A]pyrimidiner
DK1325010T3 (da) Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner
DK1326866T3 (da) Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480983

Country of ref document: EP